Jeffrey D Roizen1, Jennifer Danzig1, Veronique Groleau1, Shana McCormack1, Alex Casella1, Jennifer Harrington1, Etienne Sochett1, Andrew Tershakovec1, Babette S Zemel1, Virginia A Stallings1, Michael A Levine1. 1. Division of Endocrinology and Diabetes (J.D.R., S.M., A.C., M.A.L.), Division of General Pediatrics (J.D.), and Division of Gastroenterology, Hepatology and Nutrition (V.G., B.S.Z., V.A.S.), The Children's Hospital of Philadelphia and the Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, 19104; Division of Gastroenterology, Hepatology and Nutrition (V.G.), Ste-Justine University Hospital Center, University of Montreal, Montreal, QC, H3T 1C4 Canada; Division of Endocrinology, Department of Pediatrics (J.H., E.S.), The Hospital for Sick Children, University of Toronto, ON, M5G 1X8 Canada; Merck & Co, Inc. (A.T.), Kenilworth, New Jersey 07033.
Abstract
CONTEXT: Pseudohypoparathyroidism type 1A (PHP1A) is caused by loss-of-function mutations on the maternally inherited GNAS allele and is associated with early-onset obesity, neurocognitive defects, and resistance to multiple hormones. The role of energy intake vs central regulation of energy expenditure in the pathophysiology of obesity remains unclear. OBJECTIVE: The aim of this study was to evaluate resting energy expenditure (REE) in participants with PHP1A. DESIGN: We assessed REE, biochemical, endocrine, and auxological status of 12 participants with PHP1A who had normal or elevated body mass index; controls were a cohort of 156 obese participants. SETTING: This study took place at Children's Hospital in Philadelphia and Sick Children's Hospital in Toronto. MAIN OUTCOME MEASURES: REE as a percent of predicted REE was the outcome measure. RESULTS: PHP1A participants had normal endocrine status while receiving appropriate hormone replacement therapy, but had significantly decreased REE as a percent of predicted REE (using the modified Schofield equation). CONCLUSION: Our results are consistent with REE being the principal cause of obesity in PHP1A rather than it being caused by excessive energy intake or endocrine dysfunction.
CONTEXT: Pseudohypoparathyroidism type 1A (PHP1A) is caused by loss-of-function mutations on the maternally inherited GNAS allele and is associated with early-onset obesity, neurocognitive defects, and resistance to multiple hormones. The role of energy intake vs central regulation of energy expenditure in the pathophysiology of obesity remains unclear. OBJECTIVE: The aim of this study was to evaluate resting energy expenditure (REE) in participants with PHP1A. DESIGN: We assessed REE, biochemical, endocrine, and auxological status of 12 participants with PHP1A who had normal or elevated body mass index; controls were a cohort of 156 obeseparticipants. SETTING: This study took place at Children's Hospital in Philadelphia and Sick Children's Hospital in Toronto. MAIN OUTCOME MEASURES: REE as a percent of predicted REE was the outcome measure. RESULTS: PHP1A participants had normal endocrine status while receiving appropriate hormone replacement therapy, but had significantly decreased REE as a percent of predicted REE (using the modified Schofield equation). CONCLUSION: Our results are consistent with REE being the principal cause of obesity in PHP1A rather than it being caused by excessive energy intake or endocrine dysfunction.
Authors: Min Chen; Jie Wang; Kathryn E Dickerson; James Kelleher; Tao Xie; Divakar Gupta; Edwin W Lai; Karel Pacak; Oksana Gavrilova; Lee S Weinstein Journal: Cell Metab Date: 2009-06 Impact factor: 27.287
Authors: Giovanna Mantovani; Sara Bondioni; Andrea G Lania; Sabrina Corbetta; Luisa de Sanctis; Marco Cappa; Eliana Di Battista; Philippe Chanson; Paolo Beck-Peccoz; Anna Spada Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Kathleen L Curley; Sachini Kahanda; Katia M Perez; Beth A Malow; Ashley H Shoemaker Journal: Horm Res Paediatr Date: 2018-02-16 Impact factor: 2.852
Authors: Katia M Perez; Kathleen L Curley; James C Slaughter; Ashley H Shoemaker Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Aurora Garcia Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen A T Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Manasori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebeca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart Journal: Horm Res Paediatr Date: 2020-08-05 Impact factor: 2.852